High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014.

ABSTRACT: Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) could probably be classified as "cures". Recent publications have suggested improved efficacy, perhaps due to improved patient selection based on a better understanding of clinical features predicting outcomes. Guidelines for clinical management were established from experience at the National Cancer Institute (NCI) and an affiliation of institutions known as the Cytokine Working Group (CWG), who were among the first to utilize HD IL-2 treatment outside of the NCI. As new centers

SUBMITTER: Dutcher JP 

PROVIDER: S-EPMC6889624 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature